Form D · Biotechnology
GPN VACCINES, INC.
Wilmington, DE · CIK 0002105609
Offering snapshot reported Jan 28, 2026 · SEC filing
- Reported sold
- $3.5M Offering amount: $10M
- Investors reported
- 63 Form D · investor count
- Minimum accepted
- $228 Reported outside-investor minimum
- First sale
- Dec 24, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 28, 2026 | Initial | $3,500,000 | No comparison | 63 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-571402
Source: Form D, filed Jan 28, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Timothy Hirst | Director, Executive |
| James Selkirk | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
251 Little Falls Drive
Wilmington, DE, 19808
Wilmington, DE, 19808